

NCT ID	NCT02869217
Title	Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
Phase	Phase 1
Date Added	2016-08-16
Location	Canada
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Cyclophosphamide, Fludarabine, TBI-1301
Tags	MSS/ MMRp

NCT ID	NCT02888743
Title	Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
Phase	Phase 2
Date Added	2016-09-05
Location	Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Virginia, United States Wisconsin, United States Canada
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	durvalumab, Tremelimumab
Tags	MSS/ MMRp

NCT ID	NCT03519412
Title	Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Phase	Phase 2
Date Added	2018-05-09
Location	Italy
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	pembrolizumab (treatment), temozolomide (induction),, Keytruda, Temodar
Tags	MSS/ MMRp

NCT ID	NCT02886585
Title	Pembrolizumab In Central Nervous System Metastases
Phase	Phase 2

Date Added	2016-09-01
Location	Massachusetts, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Pembrolizumab
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT04963283
Title	Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Phase	Phase 2
Date Added	2021-07-15
Location	Colorado, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Cabozantinib, Nivolumab
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT02484404
Title	Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Phase	Phase 1, Phase 2
Date Added	2015-06-29
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Cediranib, durvalumab, Olaparib
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03365882
Title	S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Phase	Phase 2
Date Added	2017-12-07

Location	Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Puerto Rico
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	cetuximab, HER-2 testing, Irinotecan Hydrochloride, Pertuzumab, Trastuzumab, Camptosar, Erbitux, Herceptin, Perjeta
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT02298959
Title	Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
Phase	Phase 1
Date Added	2014-11-24
Location	Florida, United States Maryland, United States Massachusetts, United States Canada
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting

Drugs	Pembrolizumab, Ziv-Aflibercept, Keytruda, Zaltrap
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03657641
Title	Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2018-09-05
Location	California, United States Florida, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pembrolizumab, Regorafenib, Keytruda, Stivarga
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03296137
Title	Adoptive Cell Therapy Across Cancer Diagnoses
Phase	Phase 1/Phase 2
Date Added	2017-09-28
Location	Denmark
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Autologous tumor-infiltrating lymphocytes, Cyclophosphamide, Fludara, Ipilimumab, Nivolumab, proleukin, Opdivo, Yervoy
Tags	MSS/ MMRp